NICE recommends Idorsia's insomnia drug Quviviq

The UK's National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending Quviviq (daridorexant) for adults in England and Wales with chronic insomnia.

Idorsia’s (SIX: IDIA) dual orexin receptor antagonist has been recommended in adults with symptoms lasting for three nights or more per week for at least three months, and whose daytime functioning is considerably affected, only if cognitive behavioral therapy for insomnia has not worked or is unavailable or unsuitable.

The NICE recommends that the length of treatment with Quviviq should be as short as possible. Treatment should be assessed within three months of starting and should be stopped in people whose chronic insomnia has not responded adequately. If treatment is continued, it should be assessed at regular intervals to determine whether it is still working, according to the guidelines.